Icagen resumes trial, shares soar. Chelsea therapeutics suffers study setback. Derma sciences jumpes in AH Print
By BioMedReports.com Staff   
Wednesday, 02 February 2011 19:57
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 2, 2011.
Derma Sciences, Inc. (Nasdaq:DSCI), moved higher after the bell. The medical device and pharmaceutical company focused on advanced wound care, announced that it will issue a news release with top-line efficacy results from its Phase 2 trial with DSC127 in diabetic foot ulcers at 7:00 a.m. Eastern time Thursday, February 3 and will hold a conference call to discuss those results at 10:00 a.m. Eastern time that same day. More than 4,000 shares traded with a last tick at $10.66, up $3.99 or 60%.

After the bell, shares of Sangamo BioSciences, Inc. (Nasdaq:SGMO) got a boost as the company reported fourth quarter and full year 2010 financial results. The stock was up 84 cents or 11% to $8.49.

Icagen, Inc. (Nasdaq:ICGN) soared today after the company announced that has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed. The announcement is a result of a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy. "We are pleased with the FDA's action and will shortly be determining the next steps in the clinical development of our epilepsy drug candidate, ICA-105665," noted President and CEO P. Kay Wagoner.

ICA-105665 is an oral treatment intended to treat photosensitive epilepsy, a condition in which patients can suffer seizures after seeing bright colors or flashing lights. The company stopped a clinical trial for the drug in September 2010 after a patient taking the 600 mg dose experienced a serious side-effect.

Shares of Icagen raced to an intra-day high of $4.46 before pulling back and settling the day at $3.72, up 31 cents or 9%. More than 2 million shares traded.

Shares of Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) took a hit today after the company announced plans to modify Study 306, a late-stage study of its hypotension drug, after an interim analysis showed the trial may not meet its main goal. The drug, Northera, is being tested for the treatment of neurogenic orthostatic hypotension (NOH), a chronic and often debilitating drop in blood pressure upon standing up. The latest study was testing the drug symptomatic NOH associtaed with Parkinson disease. Approxiametly 40% of all NOH cases are linked to Parkinson's disease. Investors worry that the disappointing data could affect the drug's label, limiting the indications it could be prescribed for.

More than 5 million shares changed hands as the stock dropped $1.14 or 18.45% to $5.04.

Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens. While current prostate cancer therapies target single antigens, in this study Inovio tested the hypothesis in mice that a broader collection of antigens, administered with Inovio's electroporation-based delivery technology, would improve the breadth and effectiveness of a prostate cancer immunotherapy.

Dr. J. Joseph Kim, Inovio's President and CEO, said: "This is an important study in which the first SynCon DNA vaccine against a cancer target was successfully tested. This immunotherapy targeting more than a single antigen as a treatment for prostate cancer generated strong antibody and T-cell immune responses, which are considered vital to addressing prostate cancer. Taken together with the previous preclinical and clinical data, the current published results support the advancement of this product into a Phase I clinical study."

On heavy volume, shares hit an intra-day high of $1.50 before pulling back and closing at $1.30, up a penny.

Also Wednesday:

Amarin Corporation plc (Nasdaq:AMRN) , a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Paul E. Huff has joined the Company as Chief Commercial Officer.


Assisted Living Concepts, Inc. (NYSE:ALC) announced that it plans to release its 2010 fourth quarter financial results before the New York Stock Exchange opens on Friday, March 4, 2011.

Bionovo, Inc. (Nasdaq:BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the closing of its previously announced underwritten public offering of 30,031,200 units at a price per unit of $1.00.

Caliper Life Sciences, Inc. (Nasdaq:CALP) today announced that it has developed and optimized automation protocols on its Sciclone® NGS Workstation for Illumina's TruSeq™ DNA and TruSeq RNA sample preparation kits.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended December 31, 2010 of $64.8 million, or $0.54 per diluted share, compared to net income of $47.6 million, or $0.40 per diluted share(1), for the same period in 2009.

First China Pharmaceutical Group, Inc. (OTCBB: FCPG) a rapidly growing pharmaceutical distribution company headquartered in Yunnan, China, is pleased to announce the signing of a second exclusive drug distribution agreement further extending its vertical markets and regional penetration alongside resultantly notable revenue increases.

Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, announced that it has been contacting various health and medical insurance providers to work with them on providing coverage for its alcohol treatment program.

IDenta Corp. (PINKSHEETS: IDTA) CEO Iaacov Shoham today announced the official launch of a new casing that is able to test substances and surfaces.

Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, announced plans to release its financial results for the fourth quarter of 2010 on Tuesday, February 15, 2011 after the close of the financial markets.

NMT Medical, Inc. (NASDAQ: NMTI) today announced that the Company's securities will cease trading on The NASDAQ Capital Market and will begin trading on the OTCQB™ Marketplace effective with the open of business on February 7, 2011.

Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI).

PROLOR Biotech, Inc., (NYSE Amex:PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice.

Radient Pharmaceuticals Corporation (NYSE Amex:RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has completed the private sale of Convertible Notes and Warrants financing previously announced January 31, 2010.

Regenicin, Inc.(OTC Bulletin Board:RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs announced today that its Chairman and CEO, Randall McCoy is currently working with the board on a new Corporate incentive plan designed to encourage and reward the Company's officers, employees and consultants working with Regenicin.

Sangamo BioSciences, Inc. (Nasdaq:SGMO) today reported fourth quarter and full year 2010 financial results and accomplishments.

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce its wholly owned subsidiary Preferred Distribution Inc. is in the process of launching two new versions of its Emergency Dental Kit.

ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal second quarter ended December 31, 2010, on Thursday, February 10, 2011.

United Therapeutics Corporation (Nasdaq:UTHR) announced today that enrollment in its FREEDOM-M registration trial was completed on January 31, 2011.

Unity Management Group, Inc. (PINKSHEETS: UYMG) is a Health Resource Company specializing in Physician and Hospital Practice Management, Medical Discount Plans, Business Services, Billing Software and Technologies, along with Pharmacy Instrumentation, and Calibration.

Vapor Corp. (OTCBB: VPCO) is pleased to announce its presence at The World MoneyShow Orlando, being held February 9-12, 2011 at The Gaylord Palms Hotel & Convention Center.

Vermillion, Inc. (Nasdaq:VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company.

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Steve A. Watts, MD, was named Director of Sports Medicine, a new part-time position.

Viral Genetics (Pink Sheets:VRAL) has released its 2010 Year in Review and 2011 Outlook by CEO Haig Keledjian, available on the Company website.

 

 

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus